Importantly, the beneficial effects of FGF21 in improving NASH/MASH and other comorbidities are attributed not only to its direct effects on hepatocytes but also to its ability to induce adiponectin production in adipose tissue or through a brain–liver axis [6]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.